2022 - Automation of Solid-Phase Aromatic Foldamer Synthesis
Date2022-11-18
Deadline2022-11-18
VenueWebinar, USA - United States
KeywordsDrug Discovery; Laboratory Technology; Peptide Synthesis
Topics/Call fo Papers
The synthesis of long helical oligoamide foldamers composed of more than 20 aromatic monomers of 8-amino-2-quinoline carboxylic acid can now be routinely achieved by using an in lab-developed solid-phase foldamer synthesis (SPFS) methodology that relies on acid chloride activation.
The automation of the SPFS conditions is revolutionizing the production of high molecular weight aromatic oligoamides with very good yield and purity and faster production compared to the manual approach. That constitutes a critical milestone in the field of aromatic foldamer chemistry with many concrete applications such as the modulation of protein-protein interactions in competitive research programs.
Register for this webinar to learn more on aromatic oligoamide foldamer (AOF) chemistry, automated parallel solid-phase foldamer synthesis on the PurePep® Chorus synthesizer — a next-generation, multi-scale peptide synthesis platform — and other applications.
The automation of the SPFS conditions is revolutionizing the production of high molecular weight aromatic oligoamides with very good yield and purity and faster production compared to the manual approach. That constitutes a critical milestone in the field of aromatic foldamer chemistry with many concrete applications such as the modulation of protein-protein interactions in competitive research programs.
Register for this webinar to learn more on aromatic oligoamide foldamer (AOF) chemistry, automated parallel solid-phase foldamer synthesis on the PurePep® Chorus synthesizer — a next-generation, multi-scale peptide synthesis platform — and other applications.
Other CFPs
- The Importance of Data Integrity and Accessibility in Successful Clinical Trial Management
- Potency Assays for ATMPs — Conception, Development, Validation, Matrixed Approaches and Assay Lifecycle
- EConsent — Driving Successful Adoption
- The Changing Face of Trial Recruitment: Site-Only and Recruitment Provider Options
- Radiation Toxicity — Considerations for Implementing Radiation Dose Limits in Radiopharmaceutical Trials
Last modified: 2022-11-02 02:08:33